Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a narrative review summarizing existing knowledge about complement C5a receptors in cancer, with limited new primary data on urothelial carcinoma; it raises mechanistic questions rather than reporting a rigorous empirical result.
Phase 3 RCT with sustained reductions in disease biomarkers and clinical attack frequency from a single administration; rigorous design supports potential practice impact, though long-term durability data remain incomplete.